Anxiolytic effects of chronic treatment with Hypericum perforatum (St John’s Wort) tincture in male and female rats. by Shen, Jie Hua
Anxiolytic Effects of Chronic Treatment with 
Hypericum Perforatum (St John’s Wort) Tincture 





A thesis submitted in partial fulfilment of the requirements for the Degree of  
Master of Science in Psychology in the University of Canterbury 
By Jie Hua Shen 






I would like to thank my supervisor Professor Rob Hughes for his assistance and advice for 
this research, sharing his extensive knowledge, continued support, and time. I would also like 
to thank Dr Anthony McLean who is my secondary supervisor. In addition, I would like to 
say thank you to these kind and supportive lab technicians, Neroli, Silvana, and Emma, for 
making themselves available at the Animal Facility. Finally, I would like to thank my friends 
and also my classmates from the clinical psychology programme for their support and 
encouragement. This helped me greatly going through a difficult time of my life.  
I am grateful to the University of Canterbury Animal Committee for granting the approval. 




















Table of Contents 
Acknowledgements……………………………………………………………………………1 
Table of Contents ……………………………………………………………………………..2 
List of Tables and Figures …………………………………………………………………….3 
Abstract ……………………………………………………………………………………….4 
Introduction …………………………………………………………………………………...5 
1.1 Hypericum Perforatum (HP) …………………………………………………………6 
1.11 HP Tincture……………………………………………………………………...8 
1.2 Antidepressant Effects of HP…………………………………………………………9 
1.3 Anxiolytic Effects of HP………………………....…………………………………10 
1.4 Dosage and Withdrawal …………………………………………………………….12 
1.4.1 Dosage………………………………………………………………………...12 
1.4.2 Adverse and Withdrawal Effects …………………………………………….13 
1.5 Sex Differences……………………………………………………………………..15 
1.5.1 Sex Differences in Human Studies…………………………………………...16 
1.5.2 Sex Differences in Animal Studies…………………………………………...17 
1.6 Animal research and Behavioural Tests…………………………………………….18 




2.2 Housing and Feeding ……………………………………………………………….21 
2.3 HP Treatment and Doses …………………………………………………………...22 
2.4 General Procedure ………………………………………………………………….23 
2.5 Testing Apparatus and Behavioural Measures……………………………………...24 
2.5.1 Open Field ……………………………………………………………………24 
2.5.2 Light/dark Box………………………………………………………………..24 
2.5.3 Y Maze ……………………………………………………………………….25 
2.5.4 Elevated Zero Maze ………………………………………………………….26 
2.6 Withdrawal Testing ………………………………………………………………...27 
Results ………………………………………………………………………………………28 
3.1 Treatment Effects Data Analysis …………………………………………………..28 
3 
 
3.1.1 Open Field Measures …………………………………………………………28 
3.1.2 Light/dark Box Measures …………………………………………………….31 
3.1.3 Y Maze Measures …………………………………………………………….32 
3.1.4 Elevated Zero Maze ………………………………………………………….33 
3.2 Withdrawal Effects Data Analysis ………………………………………………….37 
3.2.1 Acute withdraw (72 hours) …………………………………………………...41 
3.2.2 Chronic Withdraw (14 days) …………………………………………………42 
Discussion …………………………………………………………………………………...44 
4.1. Summary …………………………………………………………………………..44 
4.2 Anxiolytic and Dose Effects ……………………………………………………….45 
4.3 Sex Differences …………………………………………………………………….46 
4.4 Withdrawal …………………………………………………………………………48 
4.5 Methodological Limitations ………………………………………………………..49 



















List of Tables 
Table 1: Number of rats and dose groups ……………………………………………………23 
Table 2: Values of all measures of the open field, light dark box, y maze, elevated zero maze, 
and ANOVA results of dose and sex main effects …………………………………………..35 
Table 3: Values of all measures of the open field during acute and chronic withdrawal 
periods ……………………………………………………………………………………….38 
 
List of Figures 
Figure 1: Mean centre square occupancy for male and female rats in the open field ……….30 
Figure 2: Mean entries of the light side for both male and female rats in the light dark 
box……………………………………………………………………………………………31 
Figure 3: Open area occupancy for male and female rats in the elevated zero maze ……….34 
Figure 4: Means of the transitions of each dose group across three time periods …………...39 
Figure 5: Means of the rearing behaviour of each dose group across three time periods …...40 
Figure 6: Means of the centre squares occupancy for each dose group across three time 
periods ……………………………………………………………………………………….40 
Figure 7: Means of rearing in the open field test during chronic withdraw for both male and 
female rats …………………………………………………………………………………...42 
Figure 8: Means of centre square occupancy in the open field test during chronic withdraw 









Given high prevalence of anxiety disorders, it is important to identify effective alternative 
treatments due to the current limitations of pharmacological and psychological interventions. 
Worldwide, Hypericum perforatum (HP) products have become some of the best-selling 
herbal remedies. However, empirical evidence supporting their anxiolytic effects and 
investigations of dose levels are highly scarce. To begin empirical enquiry in this field, the 
present study sought to explore treatment effects of HP following chronic oral administration 
of an HP tincture in male and female rats. Several anxiety-related responses of 74 adult rats 
(35 males and 39 females) were studied in four behavioural testing apparatuses, including the 
open field test, the light/dark box, the y maze, and the elevated zero maze. Withdrawal 
responses were also investigated upon acute (72 hours) and chronic (14 days) HP treatment-
free periods utilising the open field paradigm. Differences in anxiety responses were 
examined across sex and HP doses (0/mg/kg, 250mg/kg, 500mg/kg, and 750mg/kg). Results 
demonstrated evidence of anxiolytic effects of HP tincture and found that the 250mg/kg dose 
produced the greatest anxiolytic effect and the fewest withdrawal responses. Possible 
withdrawal responses were evident during the acute HP tincture treatment withdrawal period, 
pointing to possible anxiogenic effects upon acute discontinuation. Findings also showed sex 
differences, however, insufficient evidence was obtained from the present study with respect 
to a possible interaction between dose and sex. Despite the discussed limitations, the present 
study marked an important first step in initiating research into anxiolytic effects of 
commercially-popular herbal remedies and provides a foundation for further research into 





Anxiolytic Effects of Chronic Treatment with Hypericum Perforatum (St John’s Wort) 
Tincture in Male and Female Rats 
Anxiety disorders are being diagnosed at alarming rates. An estimated 7.3% global 
prevalence rate of anxiety disorders has been established, which illustrates that one out of 14 
people experience distress from anxiety disorders (Baxter, Scott, Vos, & Whiteford, 2013). 
Anxiety and related disorders are also the most prevalent among all psychiatric conditions 
(Kessler et al., 2005). In New Zealand, a 2012/2013 health survey reported more than 
200,000 New Zealand adults suffer from anxiety disorders, which is 6.1% of the adult 
population (Mental Health Foundation, 2014). Sex differences have also been noted in 
diagnosis rates, with women being 1.6 times more likely to have anxiety disorders in 
comparison to men (Fairbrother, Janssen, Antony, Tucker, & Young, 2016). In New Zealand, 
7.7% of women have been diagnosed with an anxiety disorder compared to 4.4% of men 
(Mental Health Foundation, 2014). These statistics establish the urgent need for adequate 
forms of treatment. However current pharmacotherapy is still limited in its effectiveness 
(Kirsch et al., 2008; Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008). The usual 
medications, such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines are 
reported to have disabling side effects including dependence, memory impairment, and 
sedation (Pittler & Ernst, 2003), whereas psychological interventions are at a much higher 
cost. Due to the limitations of current treatments, there is a rising need to investigate the use 
of alternative remedies to combat anxiety disorders especially in view of  increasing public 






1.1 Hypericum Perforatum (HP)  
Hypericum perforatum (HP), also known as St John’s Wort, has been a 
pharmaceutical aid for more than two thousand years (Istikoglou, Mavreas, & Geroulanos, 
2010). With its alleviating properties, HP has been used extensively in Europe as an 
antidepressant, antiseptic and anti-inflammatory agent, an expectorant and a tonic for the 
immune system. It is mostly studied and used for treating depression, anxiety, and sleep 
disorders in German-speaking countries (Linde, Berner, & Kriston, 2008a). In Germany, 
more than 100 million daily doses were prescribed in 2006, making HP one of the most 
widely used antidepressants (Wurglics & Schubert-Zsilavecz, 2006).  
The complex and diverse pharmacological components of HP are still being 
investigated. The yellow flowers of HP contain at least ten classes of biologically active 
detectable compounds including naphthodianthrones (hypericin and pseudohyoericin), 
anthraquinones, carotenoids, cumarine, phloroglucinols (3% hyperforin), flavonoids 
(hyperoside, quercetin and rutin), proanthocyanidins, tannins, amino acids, xanthones, 
volatile oils, and other water-soluble components (Greeson, Sanford, & Monti, 2001; 
Mullaicharam & Halligudi, 2019; Nahrstedt & Butterweck, 2010). Its antidepressant effects 
are explained by a combination of pharmacological mechanisms similar to standard 
antidepressants. However the pharmacology of HP is not yet fully understood. Multiple 
mechanisms may be involved in its antidepressant action, such as effects on serotonegic, 
noradrenergic, and dopaminergic systems, as well as GABA and glutamate amino acid 
neurotransmitters (Beckman, Sommi, & Switzer, 2000; Butterweck, 2003; Sarris, Panossian, 
Schweitzer, Stough, & Scholey, 2011). HP’s currently identified components (hyperforin, 
hypericin, and groups of flavonoids) have been reported to account for the substance’s 
neurochemical modulation (Butterweck & Schmidt, 2007).  
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Studies have shown that HP extracts are well-tolerated and have adverse reactions 
comparable to placebo (Ernst, Rand, Barnes, & Stevinson, 1998). The most frequently 
reported of these adverse effects comprise gastrointestinal irritations, allergic reactions, 
fatigue, restlessness, dizziness/confusion, tiredness/sedation and dry mouth (Ernst et al., 
1998; Woelk, Burkard, & Grunwald, 1993). However they are generally mild, transient, and 
similar to placebo, if they do occur (Melchart, 1996), and the frequency of the occurrence is 
reported to be 2% (Schmidt & Sommer, 1997, as cited in Greeson et al., 2001). 
1.11 HP Tincture 
HP supplements have been repeatedly listed as one of the top best-selling herbal 
remedies worldwide. Different forms of HP products are sold on the current market including 
liquid (ethanol or oil) tinctures, herbal teas, and dry flowers. However, no specific form of 
HP extracts has been investigated with respect to its antidepressant effects. The current body 
of research, although relatively vast, is limited in only using the pure form of HP extracts 
such as LI160 without considering the investigation of HP products that are currently 
available on the market. Investigating a particular form of the product is necessary to 
ascertain effectiveness of HP extracts and to protect consumer safety. In terms of having 
good stability of the constituents and low microbiological contamination, tinctures are 
regarded as one of the best liquid forms of plant extracts. Two different alcoholic degrees 
(40% and 60% v/v) of HP tinctures have been studied, with results yielding different levels of 
flavonol and hypericin contents, which were attributed to different decomposition 
percentages (Bilia, Bergonzi, Mazzi, & Vincieri, 2002). This finding indicates that the 





1.2 Antidepressant Effects of HP 
HP has been traditionally used in the treatment of depression. It is one of the few 
herbal remedies with a body of research supporting its clinical use. Although the actual 
mechanism of HP’s antidepressant activity has not yet been established, hypericin, one of the 
main HP constituents, is strongly associated with its antidepressant effects (Mullaicharam & 
Halligudi, 2019).  
Other findings include specific cognitive and neural processing abnormalities, such as 
negative biases in emotional processing, are thought to be a major factor in the maintenance 
of depressive symptoms. Research with depressed populations has shown attentional biases 
towards negative cues and enhanced memory for negative contexts, such as words and facial 
expressions, rather than positive information (Leppänen, 2006). The acute administration of 
an antidepressant was reported to be effective in the modification of emotional processing 
(Harmer D Phil et al., 2009). Similar to this finding, a study by Warren, Cowen, and Harmer 
(2019) demonstrated reductions in negative attentional biases and improved memory for 
positive materials with HP treatment, thereby pointing to its antidepressant potential.  
An early review Lieberman (1998) suggested that HP was safe and effective 
compared to tricyclic antidepressants (TCAs) for treating various forms of mild to moderate 
depression, without significant side effects and negative drug interactions. A meta-analysis 
conducted by Kim et al (1999) compared HP to TCAs and placebo. In the short-term 
treatment of mild to moderately severe depression, HP had similar effects to low dose TCAs, 
and was 1.5 times more likely to result in an antidepressant response than placebo. In 
addition, TCAs were reported to be more likely to cause side effects than HP. Effectiveness 
of HP was further supported by similar findings from Linde et al (2008) as well as Rahimi et 
al (2009). In their meta-analysis, Linde et al (2008) concluded that there is considerable 
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research evidence from German-speaking countries favouring the effectiveness of HP as an 
antidepressant. However, this has not been established outside of these countries. 
1.3 Anxiolytic Effects of HP  
Mood and anxiety disorders are the most prevalent psychological conditions, which 
often co-occur. It is estimated that half of individuals with depression also suffer from some 
forms of anxiety disorders (American Psychiatric, American Psychiatric, & Force, 2013). 
Currently, the only herbal remedy to be convincingly reported as having anxiolytic properties 
is Piper methysticum, also known as kava (Pittler & Ernst, 2003). However due to its 
association with hepatotoxicity, kava is currently not in clinical use and is restricted in 
several countries including the UK (Ernst, 2002).  
It is suggested that HP may have anxiolytic effects by effectively altering the 
functioning of neurotransmitters such as serotonin, dopamine, GABA, and norepinephrine. In 
addition to its use as an antidepressant, HP has also been used for anxiety disorders such as 
generalised anxiety disorder. However there is yet no empirical support for its anxiolytic 
effects (Sarris, 2013). Previous studies have focused on its application in treating depression, 
but few studies have investigated the use of HP in the treatment of anxiety disorders. 
Vandenbogaerde et al. (2000) reported some limited evidence of anxiolytic effects of HP 
extract by testing rats’ locomotor behaviour in the open field and in the light/dark box. The 
authors concluded that the potential anxiolytic activity resulted from the total extract rather 
than from a single component, such as protohypericin and a fraction containing hypericin and 
pseudohypericin. Additionally, Flausino, Zangrossi, Salgado, and Viana (2002) found some 
evidence of the HP’s therapeutic potential in anxiety by observing rats in three different 
anxiety tests (elevated T-maze, arena, light/dark box, and cat odour test) after acute and 
chronic treatments (14 consecutive days) of the HP extract, LI160. Empirical research by 
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Kumar, Garg, and Prakash (2010) also suggested that HP could be used in the treatment and 
management of stress-related conditions. They reported improved locomotor activity, 
reduced tail flick latency and anti-anxiety-like effects in mice. In a recent study from Rojas-
Carvajal, Fornaguera, Badilla, Brenes, and Calvo (2017), the anxiolytic effects of HP and 
diazepam were compared by inducing stress in anxious and depressive-like phenotype rats. 
The authors have found HP’s anxiolytic effect to be equivalent to diazepam, and concluded 
that HP may be an alternative anxiety treatment with fewer side effects, and with a wider 
safety margin. 
Since HP has been regarded as a herbal medicine rather than a health supplement, it is 
important to address its quality, efficacy, and safety. Consumers tend to use HP to treat stress, 
anxiety, and depression, believing it is a natural and safer option with fewer side effects 
compared to the standard antidepressants (Lewis, Willis, Kokanovic, & Pirotta, 2015). 
Although the majority of herbal products are reasonably safe to use (Posadzki, Watson, & 
Ernst, 2013), it is suggested that preparations of commercial HP products should be regulated 
and standardised (Bilia, Gallori, & Vincieri, 2002; Sarris, 2012). Problems can arise from 
variations in potency and number of ingredients in different brands and batches, and the 
general lack of regulation surrounding the use of HP products and appropriate doses (Ng, 
Venkatanarayanan, & Ho, 2017). Several meta-analyses have also emphasised the need for 
studies outside of German-speaking countries (Linde et al., 2008a; Rahimi, Nikfar, & 
Abdollahi, 2009). Furthermore, for the general use of HP there is still a lack of adequate 
information about its efficacy and application at different dose levels (Butterweck, 2003). 





1.4 Dosage and Withdrawal 
1.41 Dosage 
Compared to the major focus on HP’s antidepressant effects, empirical investigations 
aimed at identifying the optimal dose levels for anxiety are lacking. The recommend dosage 
by the German Commission E was 2 - 4 g of the powdered HP herb which contains 0.5 – 3 
mg of hypericin (Linde et al., 1996). However to date, there was no clear identification of the 
precise HP dose efficacy and its constituents. Few studies investigated the dose level 
efficiency or provided clear guidelines of the precise dose level(s). As previously mentioned, 
Flausino et al. (2002) tested rats’ anxiety responses upon a 14-day consumption of HP extract 
(LI 160), and compared the efficiencies of the three dose levels of 62.5, 125, 250, and 500 
mg/kg respectively. Their study concluded that the chronically treated rats with the dose level 
of 250mg/kg presented anxiolytic effects comparable to the reference drug imipramine. 
Moreover, a study from Beijamini and Andreatini (2003) tested doses of 150 and 300mg/kg 
of HP through repeated administrations over 21 days in male mice. They found anxiolytic-
like and anti-panic-like effects for the 300mg/kg dosage group but not for the 150mg/kg 
dosage group. Another study from Grundmann, Lv, Kelber, and Butterweck (2010) 
investigated doses of 125, 250, 500, and 750 mg/kg body weight in male rats for 21 days. The 
authors reported that doses of 250, 500, and 750mg/kg significantly reduced the rats’ stress 
levels. Furthermore, Negres et al. (2016) examined both acute and subacute toxicity of 
hyperforin (a major component of HP) in mice with 2000 and 5000mg/kg once per day, and 
50, 75 and 100 mg/kg for 28 days, respectively. No lethal effect occurred in the acute toxicity 
tests. The authors stated that in a single dose, hyperforin was classified as Class V toxic: 
LD50>5000mg/kg. The toxic level of hyperforin for mice has been established as a median 
lethal dose (LD50) of > 5000 mg/kg, and thus classified as Class V toxic (Negres et al., 
2016). Oral administration of a standardised 50% ethanolic extract of 100 and 200 mg/kg of 
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Indian H. perforatum once daily for three days in rat models of learning and memory resulted 
in significant attenuation of scopolamine and sodium-nitrite-induced impaired retention of 
active avoidance (Kumar, Singh, Muruganandam, & Bhattacharya, 2000).  Overall, in order 
to gain further understanding of the effectiveness of HP at different dosages, based on 
previous research, this study will define dose strengths as low (250mg/kg/day), medium 
(500mg/kg/day), and high (750mg/kg/day).  
1.42 Adverse and withdrawal effects 
HP has been reported to have a favourable side effect and withdrawal profile. Studies 
have shown that HP extracts are well-tolerated and have adverse reactions comparable to 
placebo (Ernst et al., 1998). The most frequently reported of these adverse effects comprise 
gastrointestinal irritations, allergic reactions, fatigue, restlessness, dizziness/confusion, 
tiredness/sedation and dry mouth (Ernst et al., 1998; Woelk et al., 1993). However they are 
generally mild, transient, and similar to placebo, if they do occur (Melchart, 1996), and the 
frequency of the occurrence is reported to be 2% (Schmidt & Sommer, 1997, as cited in 
Greeson et al., 2001). The adverse effects reported are mild and mostly unspecific apart from 
skin reactions from HP induced photosensitivity from bright light (Klepser & Klepser, 1999; 
Knüppel & Linde, 2004).  
It was noted that HP had fewer adverse incidents than synthesised antidepressants 
without evidence of dependency or abuse (Sarris & Kavanagh, 2009). To date, information 
regarding to the withdrawal responses of HP treatments is limited. A survey study from 
Beckman et al. (2000) found several standard antidepressants (paroxetine, fluoxetine, 
nortriptyline, desipramine, amitriptyline, and phenelzine) produced a similar withdrawal 
syndrome compared to the HP treatment that occurred during the first week of 
discontinuation. The withdrawal reactions included nausea, headache, increased anxiety, 
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irritability, dizziness, moodiness, tiredness, sleep difficulties, and influenza-like symptoms. 
However any withdrawal symptoms in the study were not related to either the dose or 
duration of use for either HP or the antidepressants.  
There is no literature currently available for providing information on any withdrawal 
effects of HP tincture treatments. Therefore previous studies of the withdrawal effects of 
antidepressants and other substances provide a foundation for the current research regarding 
to the considerations of the HP treatment free time length and assessment methods. Some rats 
studies investigated the withdrawal effects of chronic antidepressant treatments such as 
fluoxetine assessed the rats’ behaviours and neurobiological functions following 72 hours, 
12, and 14 days substance-free periods (Lin, Koob, & Markou, 1999; Stolz, Marsden, & 
Middlemiss, 1983).  Another study withdrawal effects of antidepressants on rats’ circadian 
activity rhythms from Wollnik (1992) also adopted a 14-day of drug-free period. 
Furthermore, previous studies also assessed dose and withdrawn effects of amphetamine and 
progestone in rats at 7-, 14-, and 28-day periods and analysed the measures of exploratory 
behaviours including transitions, rearing, and centre square occupancy utilising the open field 
test (Hitzemann, Tseng, Hitzemann, Sampath-Khanna, & Loh, 1977; Löfgren, Johansson, 
Meyerson, Lundgren, & Bäckström, 2006).   
From the available literature of withdrawal effect investigations, the present study will 
include an open-field test following 72 hours and two weeks of HP treatment-free periods 
respectively. However, it is important to note that currently there is no concern around 
potential side effects of HP treatments. As previously discussed, several meta-analyses have 
concluded that the rates of adverse events are comparable to placebo and lower than standard 




1.5 Sex Differences 
Since none of the reviewed studies have involved both males and females, there is no 
information about any sex-related differences in the effects of HP. Sex-based dimorphisms 
naturally occur in brain anatomy, function and neurochemistry (Jazin & Cahill, 2010). Sex-
related differences have also been found in clinical and preclinical investigations of the 
metabolism, distribution, and efficacy of antidepressants (Sramek & Cutler, 2011). Hormones 
can be responsible for triggering depressive episodes, and the fluctuations in female 
hormones may create a vulnerability for depression and anxiety for females (Parry, 1989; 
Seeman, 1997). Hughes (2019) recently surveyed publications of five journals within a 20-
month period and emphasised the need to include both sexes for studies in behavioural 
pharmacology as female subjects were excluded from most of the studies. Thus, it is essential 
that possible sex differences are considered in studies of mood disorders. 
There have been a number of attempts to explain why there are sex differences in 
depressive susceptibility, but a clear reason has not yet been determined (Sramek & Cutler, 
2011). One plausible explanation is that female hormones are responsible for triggering 
depressive episodes, and the fluctuations in female hormones are creating a vulnerability for 
depression and anxiety for females (Parry, 1989; Seeman, 1997). Other suggestions involve 
sex differences in monoamine functioning and processing (Moreno, McGahuey, Freeman, & 
Delgado, 2006); sex differences in neurotransmitter systems such as the serotonergic system 
(Legato, 1996; Nishizawa et al., 1997) and the dopaminergic system (Laakso et al., 2002), 
and acknowledged differences in cognition between men and women (Hankin & Abramson, 
2001).  
A number of sex differences have been observed  in the pharmacokinetic and 
pharmacodynamics  actions of antidepressants (Keers & Aitchison, 2010). Therefore, both 
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males and females should be included in studies of the clinical efficacy of prescribed 
antidepressants. Several years ago it was announced by the U.S. National Institutes of Health  
that research experiments  must include both sexes (Clayton & Collins, 2014). A number of 
studies of effects of antidepressants and other substances have shown sex differences in 
responsiveness to the drugs as well as their effects on brain functioning and metabolism, 
thereby supporting the need for including both sexes in psychopharmacological investigations 
(Biegon & Samuel, 1979; Carrier & Kabbaj, 2012; Gray & Hughes, 2015; Hughes & 
Hamilton, 2018; Hughes & Hancock, 2017).  
1.51 Sex Differences in Human Studies 
Studies have suggested that women may experience depression more severely and 
suffer greater functional impairment compared to males (Angst & Dobler-Mikola, 1984; 
Cahalane, Keller, & Hughes, 1994). Research has shown that depressed women tend to 
experience stronger appetites and thus greater weight gain, higher levels of anxiety, 
somatisation, anger, and more psychomotor retardation then men (Frank, Carpenter, & 
Kupfer, 1988; Kornstein et al., 2000; Perugi et al., 1990; Winokur, Coryell, Keller, Endicott, 
& Akiskal, 1993; Young, Scheftner, Fawcett, & Klerman, 1990). 
With respect to the efficacy of particular antidepressants among men and women, 
numerous studies have found significant sex differences in therapeutic responsiveness. 
Women generally have a higher proportion of body fat and adipose tissue than men, which 
may result in a wider drug distribution for lipophilic antidepressants (Yonkers & Brawman-
Mintzer, 2002; Yonkers, Kando, Cole, & Blumenthal, 1992). It is therefore reasonable to 
expect that women may require lower doses than men, or may have more adverse effects 
from antidepressants. Men and women also differ in their responses to the specific type of 
medication. An early study from Davidson and Pelton (1986) compared TCAs (imipramine 
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and amitriptyline) and MAOIs (phenelzine and isocarboxazid) among male and female 
patients with major depression, generalised anxiety, and panic disorder. For panic attacks, 
women who were treated with MAOIs responded more favourably than men, whereas men 
achieved better outcomes with TCA treatment. Overall, research findings illustrate the clear 
existence of sex-specific differences in the effectiveness of antidepressants.  
1.52 Sex Differences in Animal Studies 
Many animal studies show sex-specific effects of certain types of antidepressant in 
various brain regions. These differences have been attributed to sex differences in drug 
absorption, bioavailability, drug distribution, metabolism, and elimination. Human studies 
also suggest some similar mechanisms for sex differences during antidepressant treatment. 
There is a reasonable volume of research demonstrating sex dimorphism in response and 
adaptation to stress in rats (Dalla et al., 2008; Drossopoulou et al., 2004; Kamper et al., 
2009). Specific focus has been given to exploring how antidepressants act on the stimulation 
of synaptic plasticity and neurogenesis enhancement (Kuipers et al., 2006; Nibuya, Nestler, & 
Duman, 1996), which may differ between males and females.  
In a study by Gray and Hughes (2015) there was evidence of sex-specific effects on 
anxiety and memory in rats following over 21 days of chronic antidepressant treatment. This 
evidence consisted of dose-dependent and sex-specific effects on anxiety of the SSRI 
fluoxetine and the SNRI venlafaxine, whereas the NRI reboxetine was ineffective. For 
venlafaxine-treated males and females, low dosage in male rats showed anxiogenic effects 
through displaying higher rates of grooming behaviour while an anxiolytic effect was 
possible for females because of their decreased grooming. Although open-field behaviour did 
not show a clear pattern in sex differences, there were significant reductions in ambulation 
and rearing behaviours for fluoxetine-treated female rats only. In addition, for males only, 
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short-term spatial memory impairment may have resulted from all three drugs because of 
their impaired ability to recognise a novel change in a Y maze.  This latter finding is 
consistent with previous male-specific findings, such as impaired inhibitory avoidance in 
mice and rats, as well as impaired spatial memory in rats due to fluoxetine and venlafaxine 
treatments (Monleón, Urquiza, Arenas, Vinader-Caerols, & Parra, 2002; Sass & Wörtwein, 
2012; Ulak et al., 2006). 
1.6 Animal Research and Behavioural Tests 
Animal research is important for discovering new anxiolytic medications and for 
further understanding the neural basis of anxiety (File, 1984). The most commonly applied 
HP treatments in animal studies use the manufactured product of HP extract, LI160, which is 
currently not obtainable outside of Germany. However, none of the previous studies 
employed any commercially available HP products which are most commonly purchased and 
consumed by patients in the general public for mood disorders. Therefore, this present study 
made use of an HP tincture which is commercially manufactured and available from a local 
New Zealand supplier. The investigation was conducted with laboratory rats making use of a 
combination of four ethologically-based “unconditioned” behavioural tests (i.e., the open-
field, zero-maze, Y-maze, and light/dark box).  
These tests are designed to observe animals’ fear and anxiety in response to mildly 
stressful stimuli which do not explicitly involve pain or discomfort. In addition, they 
minimise the risk of confounding effects in the experiment caused by motivational or 
perceptual states such as hunger and learned behaviour (M. Bourin, 2015). The unconditioned 
response tests, including open field, zero-maze, and light/dark box, require no training and 
usually have a high eco/ethological validity (Steimer, 2011). Multiple tests are employed to 
assess each individual rat’s behavioural phenotype, since these tests measure anxiety under 
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different conditions (van Gaalen & Steckler, 2000). Data obtained from different tests can be 
combined to create “derived” variables which offer a more complete description of the 
individual behavioural profiles (Steimer & Driscoll, 2005).  
The chosen behavioural tests involved recording open field responses, light/dark box 
activities, Y maze arm occupations, and elevated zero maze transitions. For example, in open 
field testing, higher levels of anxiety are indicated by behavioural observations such as 
increased latencies to emerge, higher levels of grooming, corner occupancy, and defecation. 
In contrast, measures such as higher frequencies of centre occupancy, walking, and rearing 
are associated with lower levels of anxiety (Archer, 1973; Brain & Marrow, 1999). These 
tests have the advantages of being simple and do not require prior animal training (Michel 
Bourin & Hascoët, 2003).  
1.7 Aim of the Present Research 
A major goal of the present study was to investigate treatment effects of HP on 
several anxiety-related responses following chronic oral administration of an HP tincture.  
This was done by comparing rats’ anxiety responses on four behavioural tests among the HP 
tincture treatment groups and the control group. Both male and female rats of the same age 
were included in the study with approximately even numbers of each in order to explore 
possible sex differences in responses. Unlike previous studies conducted in rats that used oral 
gavage, the present investigation used a non-invasive method for chronic oral administration 
(21 days) by mixing HP tincture with rats’ drinking water. The 21-day period was selected in 
accordance with a study by Grundmann et al. (2010) of chronic restraint stress in rats. This 
study also aimed at identifying the most effective doses(s) of the HP tincture in order to 
provide some guidance for any clinical use of this product, or for self-medication. This was 
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done by testing the HP tincture’s anxiolytic effects with three target doses, namely, this study 
low (250mg/kg/day), medium (500mg/kg/day), and high (750mg/kg/day).  
It was hoped that results from the study might highlight any the anxiolytic potential of 
HP commercial products for both sexes, determine dose-related effects, and evaluate the 
safety of the product by observing any occurrence of withdrawal symptoms. In sum, the 
present study aimed to examine the anxiolytic potential of commercial HP products, compare 
its effects across sexes and different dose levels, and evaluate withdrawal symptoms, thereby 
providing further empirical evidence of the utility and safety of HP products. 
1.8 Predictions 
Four hypotheses were generated for the present study. The first goal of the study was 
to investigate the anxiolytic effects of the HP tincture. Thus, Hypothesis 1 predicted that 
anxiety responses will be lowered among rats in the HP treatment groups compared to the 
control group. 
The second aim of the study was to assess HP treatment effects with three doses so as 
to potentially detect an optimal dose level. Therefore, Hypothesis 2 predicted that there will 
be different patterns of behavioural responses among the dose groups, and that there will be 
evidence of which dose(s) produce the greatest reductions of anxiety.   
The third goal was to assess the overall dose and sex interaction effects among all the 
groups. Thus, Hypothesis 3 predicted that there will be sex differences in how each dose 
affects anxiety.  
The final aim was to determine whether any withdrawal effects occur following the 
21 days of chronic administration. Thus, Hypothesis 4 predicted that, following treatment 
discontinuation, withdrawal responses will be greater for rats in the HP treatment groups 





Subjects were 40 male and 40 female PVG/c hooded rats bred in the Animal Facility 
of the University of Canterbury’s Department of Psychology, Christchurch, New Zealand. 
The minimum number of 80 rats was determined from the result of a statistical power 
analysis for a 4 x 2 factorial ANOVA design. Forty-six of the rats (20 males and 16 females) 
were 12 days older than the remaining 44 rats (20 males and 24 females).  Because of heavy 
demands for rats and cages required by other researchers, to achieve sufficient numbers for 
the present study this slight age difference was unavoidable and beyond the control of the 
writer.  A total of six rats refused treatment consumption (five males and one female), and 
were therefore excluded from the study. 
The procedures and methods used in this study, including the housing, feeding, 
treatment, doses, procedure, and testing apparatuses, were approved by the Animal Ethics 
Committee of the University of Canterbury.  
2.2 Housing and Feeding 
All rats were weaned at 30 days after birth (PN 30) and housed in same-sexed pairs in 
opaque plastic cages measuring 560 mm x 350 mm x 215 mm (length x width x height). At 
either PN77 or PN65, the pairs were separated by means of a 560 mm x 215 mm (length x 
height) wire mesh partition. The identification of each rat was enabled by spraying one rat of 
the pair on the same side of the cages with a non-toxic, coloured branding spray. This 
housing method prevents physical contact. However it allows visual, olfactory, and auditory 
communication, thereby minimising any detrimental effects of social isolation. Both rats 
shared a common ad libitum food dispenser (commercial rat pellets). A glass bottle holding 
approximately 250 ml of drinking solution was provided for each rat in order to ensure the 
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administration of specific treatment dosage. All rats were given continuous access to their 
appropriate drinking solutions on PN 97 or PN 85 for 21 days. The housing environment was 
maintained at an ambient temperature of 22 ± 2°C and humidity of 48 ± 10% on a 12-hour 
light/dark cycle (lights on at 08:00).  
2.3 HP Treatment and Doses  
The HP drinking solutions consisted of HP tincture, plain tap water, and sucrose. The 
water-soluble HP tincture (60% ethanolic 1:2 tincture) was purchased from Weleda, a New 
Zealand local manufacturer for natural and organic products. Dose levels were based on 
previous literature describing the effects of HP on anxiety-related behaviour (Beijamini & 
Andreatini, 2003; Grundmann et al., 2010). To achieve approximate daily doses of 250, 500, 
and 750mg/kg, the quantities of HP tincture to be added to drinking water were calculated 
from records of the rats’ daily water consumption and body weights. Because male rats drink 
relatively less water in comparison to female rats (Hughes, Lowther, & van Nobelen, 2011), 
these quantities were determined separately for each sex.  For male rats, the volumes of HP 
tincture that needed to be contained in each litre of drinking water to achieve the target daily 
doses for each HP treatment group were 8.3, 16.6 and 24.8 ml respectively. For female rats, 
these volumes were 6.3, as.5 and 18.8 ml. 
In order to encourage consumption, 1% of sucrose was added to the drinking solutions 
for all groups to increase their palatability.  Table 1 presents the number of male and female 
rats in each of the four treatment groups (control and low, medium, and high dose groups). 
Once a week each rat’s bodyweight and consumption of its drinking solution were recorded 






Number of rats and dose groups   
 Control 
(Plain water) 
Low Dose HP 
(250mg/kg) 
Medium Dose HP 
(500mg/kg) 





10 9 9 7  
Number of 
Female Rats 
10 10 10 9  
Total  20 19 19 16 74 
 
2.4 General Procedure 
All behavioural testing took in place following 21 successive days of HP treatment 
(PN106 or PN118) when the rats had reached adulthood (Andersen, 2003). The rats were 
individually observed in four types of apparatus (an open field, Y maze, light/dark box and 
zero maze) with at least one day between each test. Upon the completion of all behavioural 
testing, the HP drinking solutions were replaced with plain water containing 1% sucrose. 
Following a 72-hour and 14-day HP treatment-free period respectively, possible withdrawal 
effects were investigated by performing open field tests. Random assignment and 
counterbalancing (Balanced Latin Square) were applied to ensure all the rats experienced the 
tests in different orders. In addition, the same behavioural tests were conducted during the 
same time period each day for the rats in all groups. For example, all of the open-field tests 
were conducted from 1pm to 9pm. After a rat’s test, faecal boluses were removed from the 
apparatus which was then cleaned with a 4% solution of Express Sani (a commercial 
detergent sanitiser).  
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Each type of testing apparatus was illuminated by overhead fluorescent room lighting 
of 623lx, 345lx, 406lx, and 21lx for the open field, light/dark box, Y maze, and zero maze 
respectively.  
2.5 Testing Apparatus and Behavioural Measures 
Anxiety-related (and other) responses were recorded in each type of apparatus by 
means of a momentary time-sampling procedure that involved noting the rat’s behaviour 
every 3 seconds.  Each 3-second period was indicated by an auditory signal delivered through 
an ear-piece.  Where appropriate, latencies of responding were recorded with a stopwatch, 
and entries into different parts of the apparatus were manually counted.  
2.5.1 Open Field 
The open field has become one of the most popular and convenient types of apparatus 
for measuring anxiety-like behaviours in animal research (Prut & Belzung, 2003). Prut and 
Belzung (2003) stated that the open field could trigger rodents’ agoraphobia and anxiety due 
to separation from their conspecifics. It is therefore a pertinent measure for measuring anxiety 
in rats as they are social animals and prefer to occupy small rather than large areas.  
The open field comprised a square 635 mm x 635 mm x 270 mm high wooden box 
without a lid which was painted black. A 200 mm x 150 mm x 195 mm (length x width x 
height) small wooden start box was attached to the open field with a hinged lid. The floor of 
the open field was divided into 16 equal-sized squares by means of a grid of intersecting 
white lines. The squares were numbered from 1 to 16. The corner squares were numbered 1, 
4, 13, and 16, whereas numbers 6, 7, 10, and 11 were located in the centre of the field. The 
open field was positioned on a 700 mm-high table.  
 Each individual rat was placed into the centre of the apparatus and for 5 minutes, 
every 3 seconds  the number of the square it was occupying and the type of behaviour it was 
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engaged in (walking, rearing, grooming, and immobility) were manually recorded.  At the 
end of the trial, the number of faecal boluses left by the rat in the apparatus were also 
counted. High numbers of faecal boluses are often viewed as an indication of high anxiety 
(Archer, 1973). Time spent in the centre of the field and the outer segments as well as the 
number of transitions from one square to another were also recorded.  Increased locomotor 
activity and occupation of the centre indicates lower anxiety, while less activity and a 
preference for the edges are indicators of higher anxiety levels.  
 2.5.2 Light/dark Box  
 The light/dark box has been widely used to measure anxiolytic effects of drugs and 
HP in particular (M. Bourin & Hascoet, 2003; Flausino et al., 2002; Hascoet & Bourin, 
1998). It is useful for assessing rodents’ emotional reactivity by exploiting their tendency to 
explore novel environments while avoiding illuminated areas (Hascoët, Bourin, & 
Dhonnchadha, 2001; Hughes, Desmond, & Fisher, 2004).  Anxiety in this apparatus is 
measured by observing the number of entries into and occupation of a light versus dark 
chamber.   
 This apparatus consisted of a clear-varnished wooden box, 640 mm in length, 310 mm 
in width, and 230 mm in height. It comprised a dark compartment and an illuminated 
aversive compartment (both 300 mm long x 200 mm wide x 300 mm high) separated by a 
wall with an opening (100 mm x 100 mm) and a removable slide (120 mm wide x 150 mm 
high) that enabled access to both chambers. The dark compartment was covered by a hinged 
wooden lid, whereas the light side had a hinged clear Perspex lid which allowed light into it.  
 Each rat was placed in the dark compartment of the apparatus with the lid shut and the 
partition slide closed. When the trial started, the middle slide was lifted allowing the rat free 
access to both compartments. During a 5-minute trial, the latency of first emerging into the 
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light compartment, the number of entries into each compartment, and the occupation (number 
of 3-second observations) of the light compartment were recorded. The most reliable and 
useful response for assessing anxiolytic-like activity action is the time spent in the light 
compartment (M. Bourin, 2015) .  
 2.5.3 Y Maze 
 The Y maze test is able to measure both anxiety levels and short-term memory of rats 
(Aitchison & Hughes, 2006; Hughes, 2004). The apparatus comprised a wooden un-painted 
Y maze covered by a clear Perspex lid. It was 130 mm wide and 150mm wide, and consisted 
of a 300 mm-long stem and two arms with an angle of 120° between them. The arms were 
each 460 mm long.  Each arm contained a removable black or white painted aluminium insert 
that is 400 mm long and 147 mm high. The stem was 160 mm long with a sliding partition at 
the proximal end for restricting the rat’s access to the rest of the maze i.e., the start area.  
 Testing began with an acquisition trial during which each rat was placed in the Y 
maze for a 5-minute period of free exploration with one arm containing a black insert, and the 
other containing a white insert. After this, the rat was removed and kept in a holding cage for 
approximately 30 seconds while both inserts were replaced with cleaned and disinfected 
black inserts. Then the rat was placed in the start area of the stem for a retention trial. This 
involved a 3-minute period of free exploration following removal of the the sliding partition. 
Responses recorded were the first entry of an arm and the total entries into and the number of 
3-second observations in each. These data enabled later calculation of the percent entries into 
and percent observations in the arm that had changed from white to black i.e., the novel arm.   
 2.5.4 Elevated Zero Maze  
 The elevated zero maze (EZM) is a test designed to measure anxiety by exploiting the 
natural tendencies for rats to explore a novel environment while also minimising time spent 
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in open or elevated areas. The apparatus is a reconstruction of the elevated plus maze, and is 
designed to eliminate vague interpretations of time spent in the central square of the plus 
maze (Shepherd, Grewal, Fletcher, Bill, & Dourish, 1994).  This is achieved by a smoother 
transition from closed to open areas thereby allowing the rat to walk easily from one to the 
other. The EZM was 650 mm from the floor and was supported by four metal legs to provide 
stability. It consisted of a 410 mm diameter circular platform with a track width of 45 mm 
and with two open and two enclosed areas facing each other. The corridor length of the 
enclosed areas was 740 mm with 260 mm high walls. The open-area corridors were of the 
same dimensions but were only fenced with 10 mm high edges.  
 The test began with the rats being placed in an enclosed area. The latency of first 
emergence into an open area was recorded.  Then for 5 minutes, the number of entries into 
each area was recorded along with the number of 3-second observations that the rat was seen 
in each.   
2.6 Withdrawal Testing 
Two separate open-field tests were performed at the 72 hours HP treatment free 
period and the two-week HP treatment free period respectively. The measures recorded and 
procedures followed the same process as described above for the open field test. The rats’ 
exploratory behaviours including transitions, rearing, and the centre square occupancy were 
recorded as previous studies have used these measures to assess withdrawal effects of 
nicotine, amphetamine, and progesterone (Hitzemann et al., 1977; Irvine et al., 2001; Löfgren 
et al., 2006). These investigations found that the decreases in locomotor activity (transitions 
and rearing) was indicative of an anxiogenic effect showing increased anxiety on withdrawal 





Separate 4 x 2 (dose x sex) Analyses of Variance (ANOVA) were performed on each 
response recorded in the four types of apparatus to evaluate the effects of chronic treatment 
with HP tincture, sex, and sex x treatment interactions. Additional ANOVAs were performed 
on two testing periods (HP treatment and withdrawal) for each type of apparatus. For post 
hoc comparisons, the Fisher’s Least Significant Difference (LSD) test (p<0.05) was 
performed when appropriate. The HP treatment results are presented using tables and graphs 
with means and standard error of the means (SEM’s) displayed.  
3.1 Treatment Effects Data Analysis 
Table 2 shows the means and SEM’s as well as the ANOVA results for dose and sex 
effects of all measures of the open field, light dark box, y maze, and elevated zero maze. 
3.1.1 Open Field Measures 
3.1.1.1 Walking 
  The main effect of HP dose on walking was not significant (F (3, 66) = 0.43, p = 
0.73). However, a main effect of sex differences for walking was reported (F (1, 66) = 23.82, 
p < 0.001). Results of female rats in all groups showed a significantly higher rate of walking 
than the male rats. There was no significant main interaction effect for dose and sex for 
walking.  
3.1.1.2 Rearing 
 These was no significant main effect of HP dose on rearing (F (3, 66) = 0.82, p = 
0.49). A main effect of sex differences was found to be significant (F (1, 66) = 10.76, p < 
0.001). Female rats from all dose groups showed significantly higher rearing behaviour 
compared to the male rats. There was no significant interaction effect for dose and sex (F (3, 




 For the grooming behaviour results, the main effect of HP dose was not found to be 
significant (F (3, 66) = 0.52, p = 0.67) nor was the main effect of sex differences (F (1, 66) = 
1. 50, p = 0.22). There was no main effect for dose and sex interaction (F (3, 66) = 0.59, p = 
0.63).  
3.1.1.4 Immobility 
 There was no significant main effect of HP dose on immobility (F (3, 66) = 0.94, p = 
0.43). However a main significant effect of sex was found (F (1, 66) = 25.96, p < 0.001), 
indicating that male rats from all dose groups had higher immobility rate than the female rats. 
No significant interaction effect was found for dose and sex (F (3, 66) = 0.94, p = 0.43).  
3.1.1.5 Faecal Boluses 
 The main effect of HP dose on faecal boluses was significant (F (3, 66) = 4.55, p < 
0.01). The post hoc test revealed significantly higher amount of faecal blouses for the high 
dose group compared to the other dose groups, p < 0.05. In addition, a significant main effect 
of sex differences was reported (F (1, 66) = 16.16, p < 0.001) showing that male rats from all 
dose groups produced significantly higher number of faecal boluses. There was no significant 
main interaction effect for dose and sex (F (3, 66) = 1.18, p = 0.33).  
3.1.1.6 Transitions  
 For transitions, results showed no significant main effect for HP dose (F (3, 66) = 
0.79, p = 0.51). However a main effect in sex differences was found (F (1, 66) = 35.12, p 
<0.001) indicating that the female rats from all groups had significantly more transitions 
compared to the male rats. No significant main interaction effect was found for dose and sex 
(F (3, 66) = 2.64, p = 0.06).  
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3.1.1.7 Centre Squares Occupancy 
Results for the centre squares occupancy showed a significant main effect of HP dose 
(F (3, 66) = 3.94, p < 0. 01). As shown in Figure 1, the post hoc test revealed significantly 
higher centre squares occupancy rate for the low dose group compared to the control and the 
medium dose groups. However, there was no evidence for significant main effect of sex 
difference (F (1, 66) = 1.74, p = 0.19) or for the dose and sex interaction (F (3, 66) = 0.70, p = 
0.57).  
 
Figure1. Mean centre square occupancy for male and female rats in the open field 
 
3.1.1.8 Outer Squares Occupancy 
 For the outer squares occupancy, there were no significant main effect of HP dose (F 
(3, 66) = 2.48, p = 0.07), sex difference (F (1, 66) =2.44, p =0.12), nor for the interaction 




































3.1.2 Light/dark Box Measures 
3.1.2.1 Emergence Latency 
 For emergence latency, there were no significant main effect of HP dose (F (3, 66) = 
1.63, p = 0.20); sex difference (F (1, 66) = 0.04, p = 0.84); nor for the interaction between 
dose and sex (F (3, 66) = 0.76, p = 0.52). 
3.1.2.2 Light Side Entries 
 The main effect of HP dose on light side entries was reported to be significant (F (3, 
66) = 3.31, p < 0.05). Further data analysis revealed that the low dose group had significantly 
higher light side entries compared to the control and medium dose groups. In addition, the 
difference on the light side entries between the low dose group and high dose group is 
tending towards significance with p = 0.08. Figure 2 presents the comparison of the mean 
difference in entries among the four dose groups for both male and female rats. There were 
no main effects of sex difference (F (1, 66) = 0.99, p = 0.32) and dose x sex interaction (F (3, 
66) =0.44, p = 0.73).  
 

















Mean of both sex
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3.1.2.3 Light Side Occupancy 
 For the light side occupancy, there was a significant main effect of HP dose (F (3, 66) 
= 3.55, p < 0.05). Rats from the low dose group had significantly higher light side occupancy 
rate than the control, medium, and high dose groups. There was no significant main effect of 
sex difference (F (1, 66) = 1.86, p = 0.18), and the interaction between dose and sex was 
found to be not significant (F (3, 66) = 0.78, p = 0.51).  
3.1.2.4 Dark Side Entries 
 The main effect of HP dose on dark side entries was significant (F (3, 66) = 3.27, p 
<0.05). Similar to the light side entries, results showed that the low dose group showed 
significantly higher entries rate compared to the control and medium dose groups, as which 
was  trending towards significance with p = 0.07 when compared to the high dose group. No 
significant main effect was found for sex difference (F (1, 66) = 1.53, p = 0.22), nor the dose 
and sex interaction effect (F (3, 66) = 0.32, p = 0.81).  
3.1.3 Y Maze Measures 
Data for the three male rats (each from the control, low dose, and medium dose 
groups) were excluded from the analysis due to immobility from unknown causes.  Overall 
data analysis showed no significant main effect for HP dose, sex, and dose x sex interaction 
for all of the Y maze measures including the percentage of novel arm entries and occupancy, 
and the entries into both arms.  
3.1.3.1 % Novel Arm Entries 
 There was no main effect of HP dose (F (3, 63) = 0.44, p = 0.73), sex differences (F 
(1, 63) = 1.41, p = 0.24), nor the interaction between dose and sex (F (3, 63) = 0.99, p = 0.40) 
on the measure of the percentage of novel arm entries.  
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3.1.3.2 % Novel Arm Occupancy 
Similar to novel arm entries, results of the percentage of novel arm occupancy did not 
indicate a significant main effect of HP dose (F (3, 63) = 1.31, p = 0.28), sex differences (F 
(1, 63) = 2.37, p = 0.13), nor the dose and sex interaction (F (3, 63) = 0.21, p = 0.88).  
3.1.3.3 Entries into Both Arms 
Results of both arms entries showed no significant main effect in HP dose (F (3, 63) = 
0.78, p = 0.51), sex difference (F (1, 63) = 0.02, p = 0.90), nor the dose by sex interaction (F 
(3, 63) = 0.88, p = 0.45).  
 3.1.4 Elevated Zero Maze 
For the Elevated Zero Maze, data of the four male rats (one from the control group, 
two from the low dose group, and one from the medium dose group) were excluded due to 
failure to emerge and failure to complete experimental procedures.  
3.1.4.1 Emergence Latency  
  A significant main effect of the emergence latency of the HP dose was found (F (3, 
62) = 4.79, p <0.01) showing that the rats from the high dose group took significantly longer 
time entering to the open area. Result also showed a significant main effect in sex difference 
(F (1, 62) = 14.72, p < 0.001) as well as the dose and sex interaction (F (1, 62) = 3.12, p < 
0.05). Further analysis revealed that only male rats from the high dose group took 
significantly longer time to emerge than the other dose groups (F (3, 27) = 3.69, p < 0.05). 
There was no significant differences among the dose groups for female rats (F (3, 35) = 0.65, 





3.1.4.2 % Open Area Entries 
 For the percentage of open arm entries, results showed no significant main effect of 
HP dose (F (3, 62) = 1.09, p = 0.36), sex difference (F (2, 62) = 0.33, p = 0.57), nor for the 
dose by sex interaction (F (3, 62) = 1.36, p = 0.27).  
3.1.4.3 % Open Area Occupancy 
 There was no significant main effect of HP dose for the percentage of open area 
occupancy (F (3, 62) = 1.79, p = 0.16). However the main effect of sex was significant (F (1, 
62) = 10.39, p < 0.01). Figure 3 shows that female rats occupied the open areas significantly 
longer than the male rats. No significant main effect of dose and sex interaction was found (F 
(3, 62) = 1.21, p = 0.31).  
 
Figure 3. Open area occupancy for male and female rats in the elevated zero maze 
3.1.4.4 Closed-area Entries 
 Result showed no significant main effect of HP dose on closed-area entries (F (3, 62) 
= 0.88, p = 0.46). A main effect of sex difference was reported (F (1, 62) = 16.25, p < 0.001) 
indicating that the female rats had a significantly higher entry rates to the closed-areas 
compared to the male rats. Results showed no significant main effect of the dose and sex 




































Table 2. Mean (± S.E.M, in brackets) values of all measures of the open field, light dark box, y maze, elevated zero maze, and ANOVA results of 






















n = 16 
F (3, 66) 
 
 






F (1, 66) 
 
Open field         
Walking 32.20 (1.10) 33.26 (0.87) 31.63 (1.10) 34.13 (0.74) 0.43 28.34 (0.89) 36.69 (0.79) 23.82*** 
Rearing 30.90 (1.31) 31.63 (1.12) 28.21 (1.37) 27.88 (0.61) 0.82 25.91(1.24) 33.18(0.92) 10.76*** 
Grooming 8.45 (0.82) 7.42 (0.79) 5.84 (0.62) 8.43 (0.10) 0.52 6.54 (0.71) 8.38 (0.87) 1. 50 
Immobility 28.40 (2.05) 27.68 (1.86) 34.32 (2.38) 29.56 (1.33) 0.94 39.17 (2.02) 21.74 (1.29) 25.96*** 
Faecal boluses 0.80 (0.17) 0.89 (0.16) 1.21 (0.23) 2.50 (0.27) 4.55** 2.06 (0.24) 0.62 (0.16) 16.16*** 
Transitions 43.45 (1.64) 45.84 (1.40) 41.21 (1.91) 42.06 (1.32) 0.79 35.09 (1.28) 50.46 (1.33) 35.12*** 
Centre squares 
occupancy 
3.85 (0.38) 8.26 (0.67) 4.79 (0.36) 5.81 (0.50) 3.94** 4.89 (0.61) 6.33 (0.42) 1.74 
Outer squares 
occupancy 
65.5 (1.36) 54.89 (1.52) 61.37 (1.53) 59.13 (1.46) 2.48 63.06 (1.64) 57.90 (1.35) 2.44 
         
 
Light dark box 




15.81 (1.42) 14.95 (1.41) 29.60 (4.72) 16.74 (2.28) 1.63 20.23 (3.08) 18.52 (2.65) 0.04 
Light side entries 6.40 (0.19) 8.16 (0.21) 5.89 (0.33) 6.75 (0.31) 3.31* 6.49 (0.27) 7.08 (0.29) 0.99 
Light side 
occupancy 
31.70 (1.67) 42.05 (1.03) 30.05 (1.89) 29.75 (1.39) 3.55* 35.71 (1.72) 31.54 (1.51) 1.86 
Dark side entries 6.10 (0.20) 7.79 (0.20) 5.63 (0.32) 6.38 (0.29) 3.27* 6.11 (0.26) 6.79 (0.28) 1.53 
Main significant effect * p < 0.05, ** p < 0.01, *** p < 0.001 
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n = 16 
F (3, 63) 
 
 






F (1, 63) 
 
Y maze         
% Novel arm 
entries 
61.38 (2.27) 59.33 (1.94) 57.37 (3.23) 66.47 (2.24) 0.44 58.01 (2.35) 63.44 (2.52) 1.41 
% Novel arm 
occupancy 
10.18 (0.72) 15.93 (0.99) 15.37 (1.69) 13.02 (0.95) 1.31 11.51 (0.82) 15.29 (1.35) 2.38 
Entries into both 
arms 
4.47 (0.30) 5.06 (0.23) 4.00 (0.31) 4.88 (0.27) 0.78 4.59 (0.23) 4.59 (0.31) 0.02 








38.73 (3.84) 22.81 (2.00) 35.40 (2.84) 64.27 (8.53) 4.79** 57.46 (6.61) 25.46 (2.34) 14.72*** 
% Open area 
entries 
50.47 (0.14) 51.79 (0.47) 51.09 (0.17) 51.34 (0.28) 1.09 51.31 (0.41) 51.04 (0.16) 0.33 
% Open area 
occupancy 
24.16 (1.76) 37.11 (2.36) 32.00 (2.50) 27.50 (1.69) 1.79 22.97 (2.20) 35.87 (1.86) 10.39** 
Closed-area 
entries 
6.79 (0.44) 8.22 (0.40) 7.24 (0.44) 6.69 (0.42) 0.88 5.48 (0.36) 8.64 (0.40) 16.25*** 
Main significant effect * p < 0.05, ** p < 0.01, *** p < 0.001
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3.2 Withdrawal Effects Data Analysis 
First of all, a one-way between subjects ANOVA was conducted to compare the effect 
of HP treatment time and treatment withdrawal conditions. The time period was divided into 
during treatment, treatment acute withdrawal (72 hours), and treatment chronic withdrawal 
(14 days). Measures for exploratory behaviours including transitions, rearing, and centre 
squares occupancy were analysed. Results showed a significant main effect among the three 
time periods for all of these measures: transitions (F (2, 210) = 16.83, p < 0.001), rearing (F 
(2, 210) = 14.63, p < 0.001), and centre squares occupancy (F (2, 210) = 9.02, p < 0.001). 
Table 3 shows the means and SEM’s as well as the ANOVA results for dose and sex effects 
of all measures of the open field during acute and chronic withdrawal periods. As shown by 
Figure 4, the rats’ transition rate was significantly higher during the HP treatment time period 
compared to the HP treatment free periods (p < 0.01). The transition rate was significantly 
higher for the rats tested during the chronic HP treatment withdraw period compared to those 
during the acute treatment withdrawal period (p < 0.01). Furthermore, Figure 5 shows that the 
highest rearing behaviour occurred during the HP treatment period and it was significantly 
higher than the acute HP treatment free period (p < 0.01). However it was not significantly 
higher than the chronic HP treatment free period. Figure 6 presents that rats under HP tincture 
treatment had significantly higher centre squares occupancy compared to the HP treatment 
free periods (p < 0.01). Consistent to the results of transitions, the rats’ centre squares 
occupancy rate was significantly higher during the chronic withdrawal period compared to 
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n = 16 
F (3, 66) 
 
 










        
Transitions 27.15 (1.62) 35.32 (1.50) 28.16 (1.41) 29.88 (1.28) 2.25 22.43 (1.05) 36.97 (1.36) 35.16 *** 
Rearing 18.15 (1.28) 23.68 (1.20) 21.42 (1.19) 19.13 (0.92) 1.20 16.63 (0.98) 24.21 (1.18) 11.08 *** 
Centre squares 
occupancy 
2.80 (0.28) 4.79 (0.42) 2.74 (0.25) 3.44 (0.37) 2.06 2.57 (0.28) 4.21 (0.37) 6.09 * 
         
Chronic 
withdrawal  
        
         
Transitions 34.90 (1.65) 38.58 (1.98) 37.00 (1.55) 35.38 (1.43) 0.34 27.20 (1.19) 44.82 (1.29) 44.00 *** 
Rearing 27.75 (1.42) 32.26 (2.09) 26.21 (1.26) 27.44 (0.73) 0.83 23.86 (1.43) 32.56 (1.36) 10.40 ** 
Centre squares 
occupancy 
3.05 (0.38) 4.79 (0.49) 3.68 (0.49) 2.56 (0.27) 1.43 2.94 (0.47) 4.10 (0.37) 2.49 
Main significant effect * p < 0.05, ** p < 0.01, *** p < 0.001
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Further investigation showed that the main effect of HP dose was not significant for 
transitions (F (3, 210) = 1.54, p = 0.20) and rearing (F (3, 210) = 1.85, p =0.14). However a 
significant main effect of HP dose was reported for centre squares occupancy (F (3, 210) = 
6.23, p < 0.001). Results showed that low dose group had significantly higher rate of centre 
squares occupancy than the other dose groups throughout the three testing periods. In terms 
of the time x dose interaction effect, results yielded no significance for these measures: 
transitions (F (6, 210) = 0.27, p = 0.95), rearing (F (6, 210) = 0.37, p =0.90), and centre 
squares occupancy (F (6, 210) = 0.83, p = 0.54).  However patterns of the group observations 
illustrate difference among dose groups across different time periods. Figure 4, Figure 5, and 
Figure 6 show the means of transitions, rearing, and centre square occupancy for the control 
and dose groups across treatment, acute withdrawal, and chronic withdrawal time periods. 
Rats from the low dose group have the highest transition rate and centre occupancy compared 
to the other groups regardless of different testing time periods.  
 



























































































Furthermore, separate one-way between subjects ANOVA was performed to 
investigate possible withdrawal effects during a 72-hour and 14-day HP treatment free period 
in an open field maze respectively. Table 3 displays the means, SEM’s, and the ANOVA 
results for dose and sex effects of the measures of the open field tests during acute and 
chronic withdrawal periods.  
3.2.1 Acute Withdraw (72 hours) 
3.2.1.1Transitions 
 During the acute HP treatment free period, no significant main effect was found of HP 
dose on transitions (F (3, 66) = 2.25, p = 0.09). There was a main effect of sex differences (F 
(1, 66) = 35.16, p < 0.001) indicating that the female rats crossed the squares a lot more than 
the male rats. However the main interaction effect between the dose and sex was not found (F 
(3, 66) = 1.60, p = 0.20).  
3.2.2.2 Rearing 
 There was no significant main effect of the HP dose groups of the amount of rearing 
(F (3, 66) = 1.20, p = 0.32). Results showed a significant main effect in sex difference (F (1, 
66) = 11.08, p < 0.001) with significantly higher rate of the rearing behaviour in female rats. 
There was no significant main effect in dose and sex interactions (F (3, 66) = 0.83, p = 0.48).  
3.2.2.3 Centre Squares Occupancy 
 Results for the centre squares occupancy indicated no significant main effect of HP 
dose (F (3, 66) = 2.06, p = 0.11). However post hoc test revealed that rats from the low dose 
groups had significantly higher centre square occupancy than the control and medium dose 
groups (p < 0.05). In addition, a main effect of the sex difference was found to be significant 
(F (1, 66) = 6.08, p < 0.05) showing that female rats had significantly higher rate of centre 
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area occupancy compared to the male rats. No significant main effect of dose and sex 
interaction was found (F (3, 66) = 0.40, p = 0.75).  
3.2.2 Chronic withdraw (14 days) 
3.2.2.1 Transitions 
 For the 14-day chronic HP treatment free period, there was no significant main effect 
of HP dose for transitions (F (3, 66) = 0.34, p = 0.80). A significant main effect in sex 
difference was found (F (1, 66) = 44.00, p < 0.001) showing that female rats had significantly 
higher rate of transitions than male rats. There was no significant main effect in the 
interaction between sex and dose groups (F (3, 66) = 1.69, p = 0.18).   
3.2.2.2 Rearing 
 No significant main effect was found for the HP dose on rearing (F (3, 66) = 0.83, p = 
0.48). However results showed that female rats had a significantly higher rate of rearing 
compared to the male rats (F (1, 66) = 10.40, p < 0.01) as shown in Figure 7. Although the 
pattern fluctuates among the dose groups for male and female rats, there was no significant 
main effect in dose and sex interaction.  
 





















3.2.2.3 Centre Squares Occupancy 
 For centre squares occupancy during the chronic HP treatment free period, results 
showed no significant main effect of HP dose (F (3, 66) = 1.43, p = 0.24) and sex difference 
(F (1, 66) = 2.49, p = 0.12). However a significant interaction between dose and sex was 
found (F (3, 66) = 3.96, p < 0.01). Figure 8 shows that male and female rats from the low 
dose and high dose groups had the opposite occupancy compared to these from the medium 
dose groups. 
 
Figure 8. Means of centre square occupancy in the open field test during chronic withdraw 









































The goals of this research were to (1) investigate if there is evidence to support HP’s 
anxiolytic effect by comparing rats’ anxiety responses from a control group and three dose 
groups; (2) assess if there are differences in the behavioural responses among the dose 
groups, and to detect which dose(s) produce the greatest reduction of anxiety; (3) assess sex 
differences in how each dose affect anxiety; (4) detect if there are withdrawal effects upon 
the termination of HP treatment during two time periods (acute and chronic withdrawal). To 
achieve these aims study, observations of rats responses in four behavioural tests were 
analysed using 4 x 2 (dose x sex) factorial ANOVA as well as Fisher’s LSD post hoc tests.  
Overall, the present study shows some support for the prediction that HP tincture has 
an anxiolytic effect by reducing rats’ anxiety responses in measures of centre squares 
occupancy and faecal boluses from the open field; light side entries/occupancy, and light side 
entries from the light/dark box. Apart from no observable effect in the Y maze test; the data 
analyses showed variation in the rats’ responses among the treatment and control groups 
indicating anxiolytic effects of the HP tincture treatment. Overall the results suggested that 
the low dose (250mg/kg) group displayed lower anxiety responses compared to other dose 
groups and the control group. Furthermore, there was evidence that male and females 
responded differently across measures of the open field and elevated zero maze. Evidence for 
dose and sex interaction effect was obtained on emergence latency of the elevated zero maze. 
The emergence latency was used as a measure for examining increased anxiety responses 
(Cook, Crounse, & Flaherty, 2002). This finding indicated a higher level of anxiety for the 
male rats from the high dose (750mg/kg) group as they took significantly longer time to 
emerge into the open areas. Withdrawal tests showed a higher anxiety reduction rate during 
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the treatment period compared to the treatment free periods. In addition, the low dose 
(250mg/kg) for both male and female rats appeared to produce lower anxiety than other doses 
as presented by increase locomotor activates and explorative behaviour such as number of 
transitions and percentage of time spent occupying the centre squares. These findings support 
the HP tincture’s anxiolytic effect, and the low dose (250mg/kg) as a potential optimal dose 
for both male and female rats.  
4.2 Anxiolytic and Dose Effects 
Different from Vandenbogaerde et al. (2000)’s HP extract study of reporting the 
anxiolytic effects (presented by increase number of transitions, rearing, and total pathway 
length) on the open field, this study found a higher centre squares occupancy with a specific 
dose. This evidence from the open field test showed response variation among the dose and 
control groups. A body of literature stated that rats are social animals and prefer to occupy 
small spaces rather than large open areas. The open field test is a standard neophobic anxiety 
measure in rodents. According to rats’ natural tendency to occupy the periphery of an open 
area, the open field test indicates reduced anxiety by making more entries into the central area 
and more exploratory behaviour in the apparatus (Hiroi & Neumaier, 2006; Prut & Belzung, 
2003). This study reported the anxiolytic effects and a potentially efficient dose level of the 
HP tincture treatment with supportive evidence of having the highest centre occupancy rate 
for the rats from the low dose (250mg/kg) group compared to the control and medium dose 
(500mg/kg) groups. In addition, a large number of faecal boluses is often viewed as an 
indication of higher level of anxiety (Archer, 1973). Results indicated that the HP high dose 
(750mg/kg) group produced significantly more faecal boluses representing an increased 
anxiety response. In summary, the open field test results showed highest anxiolytic effects for 




The light/dark box has been reported as a reliable measure to detect anxiolytic 
treatment effects in rodents (Crawley & Goodwin, 1980). Due to rats’ natural aversions to a  
bright light and the conflict with their tendency to explore a new area, the measure of  
locomotor activity and time spent in the light compartment indicates a lower level of anxiety 
(Belzung, Misslin, Vogel, Dodd, & Chapouthier, 1987; Hascoët et al., 2001). The results 
from this study showed a significantly higher transition as well as the light side occupancy 
rate for the low dose group. This pattern of behaviour illustrates an anxiolytic effect of the 
low dose (250 mg/kg) of the HP tincture. This finding supports the previous research in 
finding the most efficient dose for treating anxiety by showing the HP treatment at a dose 
level of 250mg/kg enhanced number of transitions between the light and dark compartments 
(Flausino et al., 2002).  
In terms of the y maze and elevated zero maze tests, there were no significant 
anxiolytic effects detected for different dose groups and the control group. However results of 
the elevated zero maze reported that the high dose group male rats took a longer period of 
time before emergence to the open area. Although this may be an indication of a higher 
anxiogenic state, however the emergence latency may not be an adequate measure for testing 
anxiogenic or anxiolytic drug effects (Matto, Harro, & Allikmets, 1997). Overall, the analysis 
revealed that the low dose (250mg/kg) had the highest anxiety reduction rate suggesting that 
this is the optimal dose for an anxiolytic effect. 
4.3 Sex Differences 
Significant sex differences were apparent in this study. Aligned with a previous mice 
study from Tucker, Fu, and McCabe (2016), findings of the present study also reported that 
female rats had increased activities levels compared to the male rats in the open field and zero 
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maze tests. However there was no evidence obtained for sex differences from the measures of 
the light/dark box, and the y maze.  
In the open field test, sex differences were evident in a number of recorded measures 
including: the amount of transitions, walking, rearing, immobility, and faecal boluses. Female 
rats appeared to be more active as presented by higher counts for transitions, walking, and 
rearing. This finding is indicative of anxiolytic effects showing higher locomotor activities 
and more explorative behaviour (Hiroi & Neumaier, 2006; Prut & Belzung, 2003; 
Vandenbogaerde et al., 2000). In contrast, male rats displayed higher frequencies of 
immobility and the number of faecal boluses indicating higher levels of anxiety (Archer, 
1973). The highest centre occupancy rate for the low dose group (250mg/kg) was apparent 
for both male and female rats in the open field test. Although there was one measure 
(transitions) suggesting a dose and sex interaction effect, this result did not reach statistical 
significance.  
In the light/dark box, sex differences were not reported to be statistically significant. 
However, the response pattern revealed that the male rats from the high dose (750mg/kg) 
group had a higher entrance rate into the light compartment than the female rats from the high 
dose group, compared to a higher entry rate for females from all the other dose groups. This 
result might be indicative that each sex has a different dosage response level.  
According to the elevated zero maze data, findings of sex differences were reported 
on open area occupancy and closed area entries which is similar to the previous experiment 
conducted by Tucker et al. (2016). This study also reported that female rats from the low dose 
group not only had significantly higher occupancy compared the females from other dose 
groups, but also than the male rats from the low dose group. This finding may suggest that 
the low dose level is the most effective dose for excreting anxiolytic effects for female rats. 
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As discussed previously, a dose and sex interaction was also shown on the measure of 
emergence latency for the male rats from the high dose group showing a possible higher 
anxiogenic state. Regardless of insufficient evidence obtained from the present study 
claiming an interaction between dose and sex, current results further support that female rats 
responded to the HP treatment differently from the male rats at a different dose level (Gray & 
Hughes, 2015).  
4.4 Withdrawal  
There is limited literature describing HP treatment withdrawal effects, and certainly 
not for HP tinctures. Behavioural measures analysed were decided according to the existing 
research on other substance studies using the open field test (Hitzemann et al., 1977; Löfgren 
et al., 2006). First of all, consistent with the first prediction of this study, anxiolytic effects of 
the HP tincture treatment was also supported by the open field withdrawal data analysis. For 
transitions, rearing, and centre area occupancy, there were significant differences among the 
HP treatment period, acute withdrawal, and the chronical withdrawal period. The results 
suggest significant anxiety reduction responses for the rats that were tested during the 
treatment time compared to the treatment free periods. Furthermore, data from the chronic 
withdrawal period showed a significantly reduced anxiety response compared to the acute 
withdrawal period which is supported by the significant increase in theses locomotor 
activities. Compared to the HP treatment and chronic withdrawal period, a withdrawal 
response was evident from the rats’ anxiety-related reduced locomotor activities during the 
acute withdrawal period. This finding is consistent with the previous study from Beckman et 
al. (2000) that claimed the production of withdrawal effect from HP treatment that was 
similar to other antidepressants after one week of treatment discontinuation.   
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The results showed no statistical significance when the main effects of dose and time 
were further investigated. A reduction of exploration was suggested thereby indicating 
reduced anxiolysis during the treatment free periods. However a consistent pattern from 
Figure 4, Figure 5, and Figure 6 shows that rats’ behaviours from the low dose (250mg/kg) 
group presents the highest anxiolytic effect across all of the three time frames. The findings 
further supported that the low dose level of 250mg/kg may have a superior anxiolytic effect 
compared to other doses (0, 500, 750 mg/kg).  
Further data analysis for the acute and chronic withdraw time periods showed 
significant sex differences respectively that is consistent with the treatment period results. 
Nonetheless, neither the acute nor the chronic withdrawal period analyses indicated a dose or 
dose x sex interaction effect. The response pattern showed an adjustment period during the 
acute treatment withdrawal phase as presented by lower locomotor activities. Overall 
evidence did not show any significant adverse effects after the HP tincture treatment 
withdrawal.  
4.5 Methodological Limitations 
This study had some limitations. Firstly, the particular HP tincture used in this study 
is not the pure form of HP extract, such as the HP LI160 used in previous clinical trials 
(Flausino et al., 2002). While the aim of this study was to investigate the possible anxiolytic 
effect of the HP tincture on the current market, it should be noted that the treatment solution 
contained HP tincture (60% ethanol 1:2 tincture), plain tap water, and sucrose (to increase 
palatability and thus encourage drinking). Therefore, the combination of ethanol and 1% of 
sucrose might also influence the rats’ behaviour. Ethanol withdrawal responses in rodents 
have been reported including hyperexcitability, stereotypic behaviour such as sniffing and 
grooming, as well as increased startle reflex and seizures (Adinoff, Majchrowicz, Martin, & 
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Linnoila, 1986; Little, Dolin, & Halsey, 1986). However, there was no evidence of such 
responses occurring in the present study. In addition, to control for any potential effect of 
sucrose, the control group had the same proportion of the sugar added to the drinking water. 
Even though there was no evidence of ethanol effects being important, it would be advisable 
for this to be controlled for in future research with HP tincture.  
Another potential limitation of this study involved the choice of the different dose 
levels which were selected on the basis of previous research (Beijamini & Andreatini, 2003; 
Flausino et al., 2002; Grundmann et al., 2010; Kumar et al., 2000). Ideally, a form of the HP 
extract would have been used. However, this was not possible due to time constraints on the 
study and the inability to obtain such an extract from the only listed supplier (in Germany), in 
spite of numerous attempts. It is possible that the HP extracts used in clinical trials (such as 
LI160) is commercially available outside of Germany which could cause difficulties for 
research into HP extracts.  
According to Bilia, Gallori, et al. (2002), two different alcoholic tinctures (40% and 
60% v/v) of HP contained different levels of flavonol and hypericin. In a review, Linde, 
Berner, and Kriston (2008b) considered HP doses of between 240 and 1800 mg and 
concluded that the composition of the products can be very different depending on the plant 
selection, extract preparation process, and the use of solvents. These findings suggest that the 
level of effectiveness of the HP tinctures can be based on the production methods and 
processes. This may pose another limitation, as this study was conducted with only one type 
of HP tincture meaning that the results may not apply to all preparations. This issue is also 
apparent in the previous studies that formulated own HP treatment by using a dry form of HP 
extract under different trademarks (A. Kumar, R. Garg, & A. K. Prakash, 2010; 
Vandenbogaerde et al., 2000).  
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4.6 Implications and Future Research 
This is the first study to investigate a HP tincture that is available on the commercial 
market. There has been considerable previous research on the antidepressant effects of HP 
extracts. However its anxiolytic potential has not been extensively studied, and sex difference 
in its effects have not been considered. In addition, there is a lack of effective dose 
information to assist in the use of HP products. This current study attempted to address some 
of these gaps.  
HP products are a highly popular alternative herbal medicine that does not require a 
doctor’s prescription and can be readily purchased by consumers. A recent review by 
Forsdike and Pirotta (2019) investigated the perception and use of HP extracts among general 
medical practitioners (GPs). The authors showed that GPs outside of Germany rarely 
recommended or prescribed HP products with poor knowledge of the herb and its 
effectiveness. The authors also expressed their concerns about HP self-medication in the 
absence of adequate clinical evidence with respect to HP extract preparations and doses. 
Therefore, the present study is a pioneer in this field aiming to provide useful information for 
health professionals and consumers.  
In addition, there are possible herb-drug interactions of HP extracts when consumed 
with other medication. Cautions have arose when co-consumption occurs for the HP products 
and other medications. Finding have reported that the HP content, with > 1 mg hyperforin 
having a potential to cause serious drug interactions (Chrubasik‐Hausmann, Vlachojannis, 
& McLachlan, 2019). Furthermore, HP extract is known to interact with mainstream 
medication for managing anxiety and depression such as Alprazolam and Amitriptyline, as 
well as other prescription drugs including Warfarin, Cyclosporine, Digoxin, HIV protease 
inhibitors, anticonvulsants, triptans, and oral contraceptives (Mullaicharam & Halligudi, 
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2019). It is necessary for future research to further investigate different dose levels with 
different forms of the HP products, and their interactions with other medication.  
In conclusion, the present study has provided some evidence supporting the anxiolytic 
effect of an HP tincture. This study has also found that the dose of 250mg/kg produced the 
greatest anxiolytic effect and the fewest withdrawal responses. Possible withdrawal responses 
were also evident during the acute HP tincture treatment withdrawal period thus suggesting 
an anxiogenic state. Overall, this is a significant first step in initiating research into popular 
herbal products such as HP extracts. Sex difference showing different levels of anxiety 
responses between male and female rats are also evident from the present study. Despite 
insufficient evidence to support an interaction effect between dose and sex, a pattern of 
different behavioural responses from male and female rats regarding to certain HP dose levels 
has been presented. It is important to recognise any effectiveness of the HP products, and to 
communicate and share the research findings with the health and mental health professionals. 
It is also recommended that consumers should seek specialists’ advice when considering 
taking HP products with other medication especially in view of the lack of regulation and the 
lack of interest in and knowledge about HP products among GPs. More research into specific 
HP products and their anxiolytic effects in relation to various dose levels should be conducted 
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